Unlock stock picks and a broker-level newsfeed that powers Wall Street.

KSE - Delayed Quote KRW

Daewoong Pharmaceutical Co., Ltd (069620.KS)

Compare
132,200.00
+2,900.00
+(2.24%)
At close: 3:30:30 PM GMT+9
Currency in KRW All numbers in thousands
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
1,422,683,296.38
1,422,683,296.38
1,221,951,076.07
1,280,091,851.01
1,152,975,698.17
Cost of Revenue
688,515,743.85
688,515,743.85
613,737,994.61
641,134,291.17
608,402,659.51
Gross Profit
734,167,552.53
734,167,552.53
608,213,081.46
638,957,559.84
544,573,038.66
Operating Expense
586,225,354
586,225,354
474,806,329
543,160,411
455,843,718
Operating Income
147,942,198.53
147,942,198.53
133,406,752.46
95,797,148.84
88,729,320.66
Net Non Operating Interest Income Expense
-1,893,559.71
-1,893,559.71
-12,022,919.70
3,674,379.42
-3,792,002.03
Pretax Income
56,550,480.23
56,550,480.23
111,631,243.18
38,329,656.95
19,761,366.30
Tax Provision
33,203,971.73
33,203,971.73
129,444.07
-833,512.38
-10,322,780.41
Net Income Common Stockholders
24,734,510.69
24,734,510.69
111,501,799.11
42,239,518.34
24,505,735.56
Basic EPS
2.15k
--
10.66k
3.82k
2.23k
Diluted EPS
2.15k
--
10.66k
3.82k
2.23k
Basic Average Shares
11,504.42
--
11,424.43
11,069.06
11,003.92
Diluted Average Shares
11,504.42
--
11,424.43
11,069.06
11,003.92
Total Operating Income as Reported
147,942,198.47
147,942,198.47
133,406,751.96
95,797,148.53
88,729,320.63
Rent Expense Supplemental
2,357,055
2,357,055
367,232
2,397,905
1,984,327
Total Expenses
1,274,741,097.85
1,274,741,097.85
1,088,544,323.61
1,184,294,702.17
1,064,246,377.51
Net Income from Continuing & Discontinued Operation
24,734,510.69
24,734,510.69
111,501,799.11
42,239,518.34
24,505,735.56
Normalized Income
60,293,597.41
60,293,597.41
116,118,533.48
49,753,748.22
22,573,427.31
Interest Income
5,092,808
5,092,808
1,126,761
4,127,645
2,553,839
Interest Expense
6,986,368
6,986,368
13,149,680
8,405,545
10,248,267
Net Interest Income
-1,893,559.71
-1,893,559.71
-12,022,919.70
3,674,379.42
-3,792,002.03
EBIT
63,536,848.23
63,536,848.23
124,780,923.18
46,735,201.95
30,009,633.30
EBITDA
112,515,244.23
112,515,244.23
160,442,023.18
86,429,865.95
70,893,074.30
Reconciled Cost of Revenue
688,515,743.85
688,515,743.85
613,737,994.61
641,134,291.17
608,402,659.51
Reconciled Depreciation
48,978,396
48,978,396
35,661,100
39,694,664
40,883,441
Net Income from Continuing Operation Net Minority Interest
24,734,510.69
24,734,510.69
111,501,799.11
42,239,518.34
24,505,735.56
Total Unusual Items Excluding Goodwill
-46,788,272
-46,788,272
-4,622,094
-10,364,455
2,576,411
Total Unusual Items
-46,788,272
-46,788,272
-4,622,094
-10,364,455
2,576,411
Normalized EBITDA
159,303,516.23
159,303,516.23
165,064,117.18
96,794,320.95
68,316,663.30
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-11,229,185.28
-11,229,185.28
-5,359.63
-2,850,225.13
644,102.75
12/31/2021 - 9/29/2005

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers